| English Alias: |
TD-4208;1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate;Revefenacin;Yupelri;GSK1160724;G2AE2VE07O;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate;1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate;Revefenacin [INN;1-[2-[[4-[[4-(Aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl N-[1,1′-biphenyl]-2-ylcarbamate (ACI);Carbamic acid, [1,1′-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl ester (9CI);1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate;TD 4208;BCP15793;Carbamic acid, N-(1,1'-biphenyl)-2-yl-, 1-(2-((4-((4-(aminocarbonyl)-1-piperidinyl)methyl)benzoyl)methylamino)ethyl)-4-piperidinyl ester;Revefenacin; TD 4208; TD4208; GSK-1160724; GSK1160724; GSK 1160724;DTXSID701027775;EX-A1722;D10978;SCHEMBL356480;1-[2-(1-{4-[(4-carbamoylpiperidin-1-yl)methyl]phenyl}-N-methylformamido)ethyl]piperidin-4-yl N-{[1,1'-biphenyl]-2-yl}carbamate;DB11855;DA-57407;REVEFENACIN [MI];SB17262;EN300-20352165;s5258;Revefenacin (USAN/INN);REVEFENACIN [ORANGE BOOK];Revefenacin [USAN:INN];Q27278649;AKOS037649398;HMS3886K17;Revefenacin [USAN:INN:WHO-DD];revefenacinum;GTPL10129;CS-7743;CCG-270187;Revefenacin;GSK1160724;NS00073361;Biphenyl-2-ylcarbamic acid 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester;CHEMBL3833319;864750-70-9;1211931-83-7;Revefenacin [INN];revefenacine;Yupelri (TN);GSK-1160724;TD4208;1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate;Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl ester; Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-;Revefenacin [WHO-DD];Biphenyl-2-ylcarbamic acid, 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester;TD-4208;1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1-biphenyl]-2-ylcarbamate;UNII-G2AE2VE07O;R03BB08;864750-70-9 (free base);BS-18189;HY-15851;REVEFENACIN [USAN];TD-4208?;TD-4208; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate;revefenacina |
Formaldehyde, polymer with (chloromethyl)oxirane and 4,4-(1-methylethylidene)bisphenol
Cas No: 28906-96-9
5-[1-methyl-1-[4-(oxiranylmethoxy)phenyl]ethyl]-2-(oxiranylmethoxy)benzyl alcohol
Cas No: 3188-83-8
2-bromo-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-6-(trifluoromethyl)aniline
Cas No: 1207314-86-0
